Grigorios Siokas Acquires 156,190 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas acquired 156,190 shares of Cosmos Health stock in a transaction on Thursday, January 8th. The shares were purchased at an average price of $0.52 per share, for a total transaction of $81,218.80. Following the completion of the acquisition, the chief executive officer directly owned 7,131,794 shares in the company, valued at $3,708,532.88. This trade represents a 2.24% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Grigorios Siokas also recently made the following trade(s):

• On Wednesday, January 7th, Grigorios Siokas purchased 124,880 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.52 per share, for a total transaction of $64,937.60.
• On Tuesday, January 6th, Grigorios Siokas purchased 133,953 shares of Cosmos Health stock. The shares were purchased at an average price of $0.54 per share, for a total transaction of $72,334.62.
• On Friday, December 19th, Grigorios Siokas acquired 88,314 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.49 per share, with a total value of $43,273.86.
• On Monday, December 15th, Grigorios Siokas bought 168,472 shares of Cosmos Health stock. The shares were acquired at an average price of $0.42 per share, for a total transaction of $70,758.24.
• On Friday, November 28th, Grigorios Siokas purchased 76,360 shares of Cosmos Health stock. The stock was acquired at an average price of $0.64 per share, with a total value of $48,870.40.
• On Tuesday, November 25th, Grigorios Siokas purchased 55,732 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.63 per share, with a total value of $35,111.16.
• On Friday, November 21st, Grigorios Siokas acquired 56,080 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.68 per share, with a total value of $38,134.40.
• On Thursday, November 20th, Grigorios Siokas bought 51,315 shares of Cosmos Health stock. The shares were bought at an average cost of $0.62 per share, for a total transaction of $31,815.30.
• On Wednesday, November 19th, Grigorios Siokas purchased 61,614 shares of Cosmos Health stock. The stock was bought at an average cost of $0.65 per share, with a total value of $40,049.10.

Cosmos Health Stock Up 9.9%

Shares of NASDAQ COSM traded up $0.05 during mid-day trading on Friday, reaching $0.57. 790,741 shares of the company were exchanged, compared to its average volume of 537,677. Cosmos Health Inc. has a 1 year low of $0.28 and a 1 year high of $1.32. The firm has a 50-day moving average of $0.58 and a 200 day moving average of $0.73. The stock has a market cap of $21.34 million, a price-to-earnings ratio of -0.76 and a beta of 5.37. The company has a quick ratio of 0.84, a current ratio of 0.99 and a debt-to-equity ratio of 0.25.

Cosmos Health (NASDAQ:COSM) last announced its earnings results on Friday, November 14th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.16). The firm had revenue of $17.11 million during the quarter, compared to the consensus estimate of $16.40 million. Cosmos Health had a negative return on equity of 33.19% and a negative net margin of 31.01%. On average, research analysts expect that Cosmos Health Inc. will post -0.78 earnings per share for the current year.

Institutional Trading of Cosmos Health

An institutional investor recently raised its position in Cosmos Health stock. Citadel Advisors LLC boosted its holdings in shares of Cosmos Health Inc. (NASDAQ:COSM) by 133.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 225,507 shares of the company’s stock after purchasing an additional 128,776 shares during the period. Citadel Advisors LLC owned about 0.65% of Cosmos Health worth $250,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 12.61% of the company’s stock.

Wall Street Analysts Forecast Growth

COSM has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Cosmos Health in a research report on Wednesday, October 8th. Wall Street Zen raised Cosmos Health to a “hold” rating in a report on Saturday, September 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cosmos Health currently has a consensus rating of “Sell”.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.